Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.12 Bn | 214.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.86% |
| Mar 31, 2026 | -393.60% |
| Dec 31, 2025 | 1,805.92% |
| Sep 30, 2025 | 153.67% |
| Jun 30, 2025 | 15,790.63% |
| Mar 31, 2025 | 100.12% |
| Dec 31, 2024 | -90.94% |
| Sep 30, 2024 | -10.72% |
| Jun 30, 2024 | 64.18% |
| Mar 31, 2024 | 42.69% |
| Dec 31, 2023 | -70.77% |
| Sep 30, 2023 | 52.01% |
| Jun 30, 2023 | -41.24% |
| Mar 31, 2023 | 25.45% |
| Dec 31, 2022 | -68.25% |
| Sep 30, 2022 | 27.76% |
| Jun 30, 2022 | 20.67% |
| Mar 31, 2022 | -317.32% |
| Dec 31, 2021 | 69.76% |
| Sep 30, 2021 | -36.12% |